All Outputs (3)

Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Bonney, S., Orchard, L., Coutinho, M., Van Tendeloo, V., Mills, K. I., Orchard, K., & Guinn, B. (2020). Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia. British journal of haematology, 189(3), 500-512. https://doi.org/10.1111/bjh.16407

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80 % of cases occur in children where ALL is well understood and treated. However it has a devastating... Read More about Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.

Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Bonney, S., Orchard, L., Coutinho, M., Van Tendeloo, V., Mills, K. I., Orchard, K., & Guinn, B. (2020). Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia. British journal of haematology, 189(3), 500-512. https://doi.org/10.1111/bjh.16407

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80% of cases occur in children where ALL is well understood and treated. However it has a devastating... Read More about Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia.

New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Freire Boullosa, L., Van Tendeloo, V., Smits, E., Mills, K. I., Orchard, K. H., & Guinn, B. A. (2020). New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. Cancer Immunology, Immunotherapy, 69(5), 867-877. https://doi.org/10.1007/s00262-020-02484-0

Acute lymphoblastic leukaemia (ALL) in adults is a rare and difficult-to-treat cancer that is characterised by excess lymphoblasts in the bone marrow. Although many patients achieve remission with chemotherapy, relapse rates are high and the associat... Read More about New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.